Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy.
BACKGROUND
After the front-line platinum-based regimens including concurrent chemoradiotherapy (CCRT) in patients with advanced or recurrent cervical cancer, platinum-based regimens are often used again.


METHODS
We retrospectively studied the predictors of response to second platinum therapy and prognostic factors of survival of 65 women who had received ≥ 2 platinum-based regimens in order to evaluate the effects of platinum-free interval (PFI), i.e., the interval between the platinum therapies.


RESULTS
The median survival and PFI were 11.0 and 11.1 months, respectively. The response rate was 42% overall and 36% in the 36 patients who had received CCRT. The response rate increased in parallel with the length of the PFI. Multivariate analyses showed a PFI for ≥ 12 months (odds ratio [OR] = 0.20), a PS of 0 (OR = 0.16) and a maximum tumor diameter ≤ 30 mm (OR = 0.18) were predictive of response. Multivariate analyses also revealed a PFI for ≥ 6 months (hazard ratio [HR] = 0.44) and a PS of 0 (HR = 0.30) were prognostic of survival.


CONCLUSIONS
Our exploratory study demonstrated that PFI has both predictive and prognostic value for second platinum therapy in patients with advanced or recurrent cervical cancer.
Tanioka
Maki
M
National Cancer Center Hospital, Tokyo, Japan. tanioka@hp.pref.hyogo.jp
Katsumata
Noriyuki
N
Yonemori
Kan
K
Kouno
Tsutomu
T
Shimizu
Chikako
C
Tamura
Kenji
K
Ando
Masashi
M
Fujiwara
Yasuhiro
Y
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D047368:Tumor Burden; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin